Add Post-Exposure Prophylaxis to Regen-COV Protocols

You'll hear buzz about using casirivimab/imdevimab (Regen-COV) to PREVENT COVID-19...especially as cases continue to rise.

You already use this monoclonal antibody combo to TREAT mild to moderate COVID-19 in outpatients age 12 or older at high risk of severe illness.

Many patients are considered at high risk, such as those with diabetes...age 65 or older...or even with a BMI over 25.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals